Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,578,610

« Back to Dashboard

Patent 5,578,610 protects ALLEGRA, CHILDREN'S ALLEGRA ALLERGY, CHILDREN'S ALLEGRA HIVES, ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, ALLEGRA ALLERGY, and ALLEGRA HIVES, and is included in seven NDAs. There has been one Paragraph IV challenge on Allegra. There are five tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for ALLEGRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,578,610

Title: Piperidine derivatives
Abstract:The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
Inventor(s): D'Ambra; Thomas E. (Wynantskill, NY)
Assignee: Albany Molecular Research, Inc. (Albany, NY)
Application Number:08/456,273
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
ALLEGRA
fexofenadine hydrochloride
SUSPENSION;ORAL021963Oct 16, 2006RXYes5,578,610<disabled>YYRELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909Jan 24, 2011OTCYes5,578,610<disabled>YYRELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Sanofi Aventis Us
CHILDREN'S ALLEGRA HIVES
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909Jan 24, 2011OTCYes5,578,610<disabled>YYRELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Sanofi Aventis Us
ALLEGRA
fexofenadine hydrochloride
CAPSULE;ORAL020625Jul 25, 1996DISCNNo5,578,610*PED<disabled>Y
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373Jan 24, 2011OTCYes5,578,610*PED<disabled>Y
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,578,610

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)9500482Jan 05, 1995
United States of America5581011Dec 03, 1996
United States of America5589487Dec 31, 1996
United States of America5663412Sep 02, 1997
United States of America5750703May 12, 1998
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc